we have adopted remote working tools to minimize the disruption to the achievement of our goals and objectives for employees whose job duties do not require physical presence to complete their work . certain manufacturing , quality and laboratory-based employees have continued to work onsite , and certain employees with customer-facing roles are onsite for training and interfacing in-person with customers in connection with the product launch of the rha® collection of dermal fillers . if the severity , duration or nature of the covid-19 pandemic changes , it may have an impact on our ability to continue on-site operations , which could disrupt our clinical trials and sales activities . the covid-19 pandemic has and may continue to negatively affect our ability to obtain approval of product candidates from the fda or other regulatory authorities , supply chain , end user demand for our products and commercialization activities . in november 2020 , the fda deferred a decision on the bla for daxibotulinumtoxina for injection for the treatment of moderate to severe glabellar ( frown ) lines . the fda reiterated that an inspection of our manufacturing facility is required as part of the bla approval process , but the fda was unable to conduct the required inspection of our manufacturing facility in newark , california , due to the fda 's travel restrictions associated with the covid-19 pandemic . the fda did not indicate there were any other review issues at the time beyond the on-site inspection . in addition , the product supply of the rha® collection of dermal fillers was delayed by distribution partner teoxane as they temporarily suspended production in geneva , switzerland as a precaution surrounding the covid-19 pandemic . teoxane resumed manufacturing operations at the end of april 2020 and delivered the first shipment of the rha® collection of dermal fillers to us in june 2020. as a result , our initial product launch of the rha® collection of dermal fillers was delayed by one quarter to september 2020. in addition , port closures and other restrictions resulting from the 86 covid-19 pandemic may disrupt our supply chain or limit our ability to obtain sufficient materials for the production of our products . we have taken steps to build sufficient levels of inventory to help mitigate potential future supply chain disruptions . our clinical trials have been and may continue to be affected by the covid-19 pandemic . the covid-19 pandemic has and may further delay enrollment in and the progress of our current and future clinical trials . patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services . site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the covid-19 pandemic . for example , enrollment in the juniper phase 2 adult upper limb spasticity trial was paused in march 2020 due to challenges related to the covid-19 pandemic . the trial was originally designed to include 128 subjects . due to the covid-19 challenges related to continued subject enrollment and the scheduling of in-person study visits , in june 2020 , we announced the decision to end screening and complete the juniper trial with the 83 patients enrolled to date . we released topline results from the phase 2 study in february 2021. to ensure proper clinical trial coordination and completion , in line with the fda-issued guidance of march 18 , 2020 on the conduct of clinical trials of medical products during the covid-19 pandemic , we are evaluating and implementing risk-based approaches for remote clinical trial monitoring and activities , including remote patient assessment , for those subjects who can not physically visit clinic sites , to ensure the full completion of trials . the ultimate impact of the covid-19 pandemic is highly uncertain and we do not yet know the full extent of potential delays or impacts on our bla , our manufacturing operations , supply chain , end user demand for our products and services , commercialization efforts , business operations , clinical trials and other aspects of our business , the healthcare systems or the global economy as a whole . as such , it is uncertain as to the full magnitude that the covid-19 pandemic will have on our financial condition , liquidity , and results of operations . financial update at-the-market offerings in november 2020 , we terminated our controlled equity offering sale agreement with cantor fitzgerald & co. ( the `` 2018 atm agreement `` ) and entered into a separate sales agreement with cowen and company , llc ( `` cowen `` ) as sales agent ( the “ 2020 atm agreement ” ) . under the 2020 atm agreement , we may offer and sell , from time to time , through cowen , shares of our common stock , par value $ 0.001 per share , having an aggregate offering price of up to $ 125.0 million . as of february 17 , 2021 , we sold 3.3 million shares of common stock under the 2020 atm agreement resulting in net proceeds of $ 90.1 million after sales agent commissions . convertible senior notes on february 14 , 2020 , we issued $ 287.5 million aggregate principal amount of the 2027 notes , pursuant to the indenture . the 2027 notes are senior unsecured obligations and bear interest at a rate of 1.75 % per year , payable semiannually in arrears on february 15 and august 15 of each year , beginning on august 15 , 2020. the 2027 notes will mature on february 15 , 2027 , unless earlier converted , redeemed or repurchased . in connection with issuing the 2027 notes , we received $ 278.3 million in net proceeds , after deducting the initial purchasers ' discount , commissions , and other issuance costs . story_separator_special_tag we began the continuation phase of the onabotulinumtoxina biosimilar program and are moving forward with characterization and product development work , followed by an anticipated filing of an investigational new drug application ( “ ind ” ) with the fda in 2022. results of operations a discussion regarding our financial condition and results of operations for the year ended december 31 , 2020 compared to the same period in 2019 is presented below . for a discussion regarding our financial condition and results of operations for the year ended december 31 , 2019 compared to the same period in 2018 , see part ii , item 7 . “ management 's discussion and analysis of financial condition and results of operations—results of operations ” of our annual report on form 10-k for the year ended december 31 , 2019 , as filed with the sec on february 26 , 2020. as a result of the hintmd acquisition in july 2020 , we have two reportable segments : the product segment and the service segment . our product segment refers to the business that includes the research and development of innovative aesthetic and therapeutic products , including daxibotulinumtoxina for injection for various indications , the u.s. distribution of the rha® collection of dermal fillers , and the onabotulinumtoxina biosimilar program in partnership with viatris . both product and collaboration revenues and related expenses are included in product segment . our service segment refers to the business of the hintmd platform , which is a registered payfac and enables practices to process payments for their patients and provides subscription and pay-over-time solutions that support practices ' aesthetic treatment plans . revenue replace_table_token_1_th n/m - percentage not meaningful product revenue we currently generate product revenue primarily from the sale of the rha® collection of dermal fillers . we made initial sales of the rha® collection of dermal fillers in june 2020 as a part of the prevu program and the formal commercial launch took place in september 2020. for additional information on the prevu program , please read part i , item 1 . “ business — sales and marketing ” . collaboration revenue for the year ended december 31 , 2020 , our collaboration revenue recognized increased compared to the same periods in 2019 due to the increased development activities in connection with the viatris collaboration . in june 2020 , we announced that viatris provided us its written notice of its continuation decision . service revenue our service revenue is generated from the hintmd platform , which earns revenues through : ( i ) credit card processing revenues net of interchange and other fees and ( ii ) monthly per patient fees for practices that use the subscription capabilities . we completed the hintmd acquisition in july 2020 . 91 in our current platform service agreements , we generally recognize service revenue net of costs as an accounting agent . revenue recognized in new or revised future service offerings and arrangements may be presented differently subject to the accounting evaluation of control . please also read our revenue accounting policies in part iv , item 15 . “ exhibits and financial statement schedules—notes to consolidated financial statements— note 2 —summary of significant accounting policies ” in this annual report on form 10-k. operating expenses replace_table_token_2_th our operating expenses consist of costs of product revenue ( exclusive of amortization ) and cost of service revenue ( exclusive of amortization ) , research and development expenses , selling , general and administrative expenses , and amortization . the largest component of our operating expenses is our personnel costs including stock-based compensation , which is a subset of our selling , general and administrative expenses . we expect our operating expenses to increase in the near term as we continue to commercialize the rha® collection of dermal fillers in the u.s. and the next-generation hintmd platform , account for the full year impact of an expanded organization related to the hintmd acquisition and the hiring of our sales force , and other actions taken to prepare for the commercialization of daxibotulinumtoxina for injection for the treatment of glabellar lines if our bla is approved in 2021. we also expect to decrease our operating expenses related to research and development as we complete existing clinical trials and associated programs related to daxibotulinumtoxina for injection for the treatment of cervical dystonia , adult upper limb spasticity , plantar fasciitis , offset by future potential new indications , and an onabotulinumtoxina biosimilar , as well as the impact of capitalized inventory costs of daxibotulinumtoxina for injection , if approved . cost of product revenue ( exclusive of amortization ) the costs of product revenue ( exclusive of amortization ) primarily consists of the cost of inventory and distribution expenses related to the rha® collection of dermal fillers . we did not incur costs of product revenue until the first delivery of the rha® collection of dermal fillers in the second quarter of 2020. cost of service revenue ( exclusive of amortization ) the costs of service revenue ( exclusive of amortization ) consist of limited costs in fulfilling certain services provided by the hintmd platform . we did not incur cost of service revenue related to fulfillment of services until the completion of the hintmd acquisition in july 2020. selling , general and administrative expenses selling , general and administrative expenses consist primarily of the following : rha® collection of dermal fillers and hintmd platform service sales and marketing activities and compensation costs of our sales force ; daxibotulinumtoxina for injection pre-commercial activities such as market research and public relations ; 92 personnel and professional service costs in our finance , information technology , commercial , investor relations , legal , human resources , and other administrative functions , including related stock-based compensation costs ; and depreciation and amortization of certain assets used in selling , general and administrative activities . we expect that our selling ,

liquidity and capital resources our financial condition is summarized as follows : replace_table_token_6_th sources and uses of cash we hold our cash , cash equivalents , and short-term investments in a variety of non-interest bearing bank accounts and interest-bearing instruments subject to investment guidelines allowing for certain lower-risk holdings such as , but not limited to , money market accounts , u.s. treasury securities , u.s. government and agency securities , overnight purchase agreements , and commercial paper . our investment portfolio is structured to provide for investment maturities and access to cash to fund our anticipated working capital needs . as of december 31 , 2020 and 2019 , we had cash , cash equivalents and short-term investments of $ 436.5 million and $ 290.1 million , respectively , which represented an increase of $ 146.4 million from december 31 , 2019 to december 31 , 2020. the increase was primarily due to the proceeds from the issuance of convertible senior notes of $ 287.5 million , the issuance of shares of our common stock in connection with an at-the-market offering program , net of commissions , of $ 68.4 million , the issuance of shares of our common stock in january 2020 in connection with the exercise of the over-allotment option in the december 2019 follow-on public offering ( described below ) , net of underwriting discounts and commissions , of $ 15.6 million , the $ 30.0 million cash milestone payment from viatris , the proceeds from the exercise of stock options , common stock warrants and the purchase of shares of our common stock under the 2014 espp of $ 6.9 million .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources our financial condition is summarized as follows : replace_table_token_6_th sources and uses of cash we hold our cash , cash equivalents , and short-term investments in a variety of non-interest bearing bank accounts and interest-bearing instruments subject to investment guidelines allowing for certain lower-risk holdings such as , but not limited to , money market accounts , u.s. treasury securities , u.s. government and agency securities , overnight purchase agreements , and commercial paper . our investment portfolio is structured to provide for investment maturities and access to cash to fund our anticipated working capital needs . as of december 31 , 2020 and 2019 , we had cash , cash equivalents and short-term investments of $ 436.5 million and $ 290.1 million , respectively , which represented an increase of $ 146.4 million from december 31 , 2019 to december 31 , 2020. the increase was primarily due to the proceeds from the issuance of convertible senior notes of $ 287.5 million , the issuance of shares of our common stock in connection with an at-the-market offering program , net of commissions , of $ 68.4 million , the issuance of shares of our common stock in january 2020 in connection with the exercise of the over-allotment option in the december 2019 follow-on public offering ( described below ) , net of underwriting discounts and commissions , of $ 15.6 million , the $ 30.0 million cash milestone payment from viatris , the proceeds from the exercise of stock options , common stock warrants and the purchase of shares of our common stock under the 2014 espp of $ 6.9 million .
```    
 Suspicious Activity Report : we have adopted remote working tools to minimize the disruption to the achievement of our goals and objectives for employees whose job duties do not require physical presence to complete their work . certain manufacturing , quality and laboratory-based employees have continued to work onsite , and certain employees with customer-facing roles are onsite for training and interfacing in-person with customers in connection with the product launch of the rha® collection of dermal fillers . if the severity , duration or nature of the covid-19 pandemic changes , it may have an impact on our ability to continue on-site operations , which could disrupt our clinical trials and sales activities . the covid-19 pandemic has and may continue to negatively affect our ability to obtain approval of product candidates from the fda or other regulatory authorities , supply chain , end user demand for our products and commercialization activities . in november 2020 , the fda deferred a decision on the bla for daxibotulinumtoxina for injection for the treatment of moderate to severe glabellar ( frown ) lines . the fda reiterated that an inspection of our manufacturing facility is required as part of the bla approval process , but the fda was unable to conduct the required inspection of our manufacturing facility in newark , california , due to the fda 's travel restrictions associated with the covid-19 pandemic . the fda did not indicate there were any other review issues at the time beyond the on-site inspection . in addition , the product supply of the rha® collection of dermal fillers was delayed by distribution partner teoxane as they temporarily suspended production in geneva , switzerland as a precaution surrounding the covid-19 pandemic . teoxane resumed manufacturing operations at the end of april 2020 and delivered the first shipment of the rha® collection of dermal fillers to us in june 2020. as a result , our initial product launch of the rha® collection of dermal fillers was delayed by one quarter to september 2020. in addition , port closures and other restrictions resulting from the 86 covid-19 pandemic may disrupt our supply chain or limit our ability to obtain sufficient materials for the production of our products . we have taken steps to build sufficient levels of inventory to help mitigate potential future supply chain disruptions . our clinical trials have been and may continue to be affected by the covid-19 pandemic . the covid-19 pandemic has and may further delay enrollment in and the progress of our current and future clinical trials . patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services . site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the covid-19 pandemic . for example , enrollment in the juniper phase 2 adult upper limb spasticity trial was paused in march 2020 due to challenges related to the covid-19 pandemic . the trial was originally designed to include 128 subjects . due to the covid-19 challenges related to continued subject enrollment and the scheduling of in-person study visits , in june 2020 , we announced the decision to end screening and complete the juniper trial with the 83 patients enrolled to date . we released topline results from the phase 2 study in february 2021. to ensure proper clinical trial coordination and completion , in line with the fda-issued guidance of march 18 , 2020 on the conduct of clinical trials of medical products during the covid-19 pandemic , we are evaluating and implementing risk-based approaches for remote clinical trial monitoring and activities , including remote patient assessment , for those subjects who can not physically visit clinic sites , to ensure the full completion of trials . the ultimate impact of the covid-19 pandemic is highly uncertain and we do not yet know the full extent of potential delays or impacts on our bla , our manufacturing operations , supply chain , end user demand for our products and services , commercialization efforts , business operations , clinical trials and other aspects of our business , the healthcare systems or the global economy as a whole . as such , it is uncertain as to the full magnitude that the covid-19 pandemic will have on our financial condition , liquidity , and results of operations . financial update at-the-market offerings in november 2020 , we terminated our controlled equity offering sale agreement with cantor fitzgerald & co. ( the `` 2018 atm agreement `` ) and entered into a separate sales agreement with cowen and company , llc ( `` cowen `` ) as sales agent ( the “ 2020 atm agreement ” ) . under the 2020 atm agreement , we may offer and sell , from time to time , through cowen , shares of our common stock , par value $ 0.001 per share , having an aggregate offering price of up to $ 125.0 million . as of february 17 , 2021 , we sold 3.3 million shares of common stock under the 2020 atm agreement resulting in net proceeds of $ 90.1 million after sales agent commissions . convertible senior notes on february 14 , 2020 , we issued $ 287.5 million aggregate principal amount of the 2027 notes , pursuant to the indenture . the 2027 notes are senior unsecured obligations and bear interest at a rate of 1.75 % per year , payable semiannually in arrears on february 15 and august 15 of each year , beginning on august 15 , 2020. the 2027 notes will mature on february 15 , 2027 , unless earlier converted , redeemed or repurchased . in connection with issuing the 2027 notes , we received $ 278.3 million in net proceeds , after deducting the initial purchasers ' discount , commissions , and other issuance costs . story_separator_special_tag we began the continuation phase of the onabotulinumtoxina biosimilar program and are moving forward with characterization and product development work , followed by an anticipated filing of an investigational new drug application ( “ ind ” ) with the fda in 2022. results of operations a discussion regarding our financial condition and results of operations for the year ended december 31 , 2020 compared to the same period in 2019 is presented below . for a discussion regarding our financial condition and results of operations for the year ended december 31 , 2019 compared to the same period in 2018 , see part ii , item 7 . “ management 's discussion and analysis of financial condition and results of operations—results of operations ” of our annual report on form 10-k for the year ended december 31 , 2019 , as filed with the sec on february 26 , 2020. as a result of the hintmd acquisition in july 2020 , we have two reportable segments : the product segment and the service segment . our product segment refers to the business that includes the research and development of innovative aesthetic and therapeutic products , including daxibotulinumtoxina for injection for various indications , the u.s. distribution of the rha® collection of dermal fillers , and the onabotulinumtoxina biosimilar program in partnership with viatris . both product and collaboration revenues and related expenses are included in product segment . our service segment refers to the business of the hintmd platform , which is a registered payfac and enables practices to process payments for their patients and provides subscription and pay-over-time solutions that support practices ' aesthetic treatment plans . revenue replace_table_token_1_th n/m - percentage not meaningful product revenue we currently generate product revenue primarily from the sale of the rha® collection of dermal fillers . we made initial sales of the rha® collection of dermal fillers in june 2020 as a part of the prevu program and the formal commercial launch took place in september 2020. for additional information on the prevu program , please read part i , item 1 . “ business — sales and marketing ” . collaboration revenue for the year ended december 31 , 2020 , our collaboration revenue recognized increased compared to the same periods in 2019 due to the increased development activities in connection with the viatris collaboration . in june 2020 , we announced that viatris provided us its written notice of its continuation decision . service revenue our service revenue is generated from the hintmd platform , which earns revenues through : ( i ) credit card processing revenues net of interchange and other fees and ( ii ) monthly per patient fees for practices that use the subscription capabilities . we completed the hintmd acquisition in july 2020 . 91 in our current platform service agreements , we generally recognize service revenue net of costs as an accounting agent . revenue recognized in new or revised future service offerings and arrangements may be presented differently subject to the accounting evaluation of control . please also read our revenue accounting policies in part iv , item 15 . “ exhibits and financial statement schedules—notes to consolidated financial statements— note 2 —summary of significant accounting policies ” in this annual report on form 10-k. operating expenses replace_table_token_2_th our operating expenses consist of costs of product revenue ( exclusive of amortization ) and cost of service revenue ( exclusive of amortization ) , research and development expenses , selling , general and administrative expenses , and amortization . the largest component of our operating expenses is our personnel costs including stock-based compensation , which is a subset of our selling , general and administrative expenses . we expect our operating expenses to increase in the near term as we continue to commercialize the rha® collection of dermal fillers in the u.s. and the next-generation hintmd platform , account for the full year impact of an expanded organization related to the hintmd acquisition and the hiring of our sales force , and other actions taken to prepare for the commercialization of daxibotulinumtoxina for injection for the treatment of glabellar lines if our bla is approved in 2021. we also expect to decrease our operating expenses related to research and development as we complete existing clinical trials and associated programs related to daxibotulinumtoxina for injection for the treatment of cervical dystonia , adult upper limb spasticity , plantar fasciitis , offset by future potential new indications , and an onabotulinumtoxina biosimilar , as well as the impact of capitalized inventory costs of daxibotulinumtoxina for injection , if approved . cost of product revenue ( exclusive of amortization ) the costs of product revenue ( exclusive of amortization ) primarily consists of the cost of inventory and distribution expenses related to the rha® collection of dermal fillers . we did not incur costs of product revenue until the first delivery of the rha® collection of dermal fillers in the second quarter of 2020. cost of service revenue ( exclusive of amortization ) the costs of service revenue ( exclusive of amortization ) consist of limited costs in fulfilling certain services provided by the hintmd platform . we did not incur cost of service revenue related to fulfillment of services until the completion of the hintmd acquisition in july 2020. selling , general and administrative expenses selling , general and administrative expenses consist primarily of the following : rha® collection of dermal fillers and hintmd platform service sales and marketing activities and compensation costs of our sales force ; daxibotulinumtoxina for injection pre-commercial activities such as market research and public relations ; 92 personnel and professional service costs in our finance , information technology , commercial , investor relations , legal , human resources , and other administrative functions , including related stock-based compensation costs ; and depreciation and amortization of certain assets used in selling , general and administrative activities . we expect that our selling ,

